Matthias G. Schroff
Chief Executive Officer chez Inceptor Bio LLC
Fortune : 150 $ au 31/03/2024
Profil
Matthias G.
Schroff is currently the Chief Executive Officer at Inceptor Bio LLC since 2023 and the Chief Operating Officer at Exicure Operating Co. since 2018.
Previously, he was the Chief Executive Officer at Vaximm AG from 2016 to 2017, the President, Chief Executive Officer & Director at Exicure, Inc. from 2018 to 2023, and a Member-Executive Board at MOLOGEN AG from 2005 to 2015.
He was also a Member-Supervisory Board at Verband Forschender Arzneimittelhersteller eV.
Schroff received his undergraduate degree from the University of Hannover and his doctorate from Freie Universität Berlin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EXICURE, INC.
0,00% | 27/04/2023 | 250 ( 0,00% ) | 150 $ | 31/03/2024 |
Postes actifs de Matthias G. Schroff
| Sociétés | Poste | Début |
|---|---|---|
Exicure Operating Co.
 Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Chief Operating Officer | 01/04/2018 |
Inceptor Bio LLC
 Inceptor Bio LLC BiotechnologyHealth Technology Inceptor Bio LLC operates as a biotechnology industry company. The company is headquartered in Raleigh, NC. | Chief Executive Officer | 08/05/2023 |
Anciens postes connus de Matthias G. Schroff
| Sociétés | Poste | Fin |
|---|---|---|
| EXICURE, INC. | Chief Executive Officer | 26/04/2023 |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Chief Executive Officer | 31/12/2017 |
| MOLOGEN AG | Chief Executive Officer | 01/11/2015 |
Verband Forschender Arzneimittelhersteller eV
 Verband Forschender Arzneimittelhersteller eV Miscellaneous Commercial ServicesCommercial Services Verband Forschender Arzneimittelhersteller eV, founded in 1994, is an association of researching pharmaceutical companies in Germany. The private company is based in Berlin, Germany. The German company's main focus is on the drugs and therapies currently being researched in the industry. | Director/Board Member | - |
Formation de Matthias G. Schroff
| University of Hannover | Undergraduate Degree |
| Freie Universität Berlin | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MOLOGEN AG | Commercial Services |
| EXICURE, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Verband Forschender Arzneimittelhersteller eV
Verband Forschender Arzneimittelhersteller eV Miscellaneous Commercial ServicesCommercial Services Verband Forschender Arzneimittelhersteller eV, founded in 1994, is an association of researching pharmaceutical companies in Germany. The private company is based in Berlin, Germany. The German company's main focus is on the drugs and therapies currently being researched in the industry. | Commercial Services |
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Inceptor Bio LLC
Inceptor Bio LLC BiotechnologyHealth Technology Inceptor Bio LLC operates as a biotechnology industry company. The company is headquartered in Raleigh, NC. | Health Technology |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
